Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Fine Foods & Pharmaceuticals NTM SpA EV-to-EBIT?
Fine Foods & Pharmaceuticals NTM SpAFRA:9S5 -1.92%63 EV-to-EBIT is 17.51 as of Sep. 11, 2026, which is 1% above its 10-year median of 17.30. GuruFocus rates FRA:9S5 with a GF Score™ of 63/100 and a GF Value™ of €8.87 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,565 Consumer Packaged Goods companies, Fine Foods & Pharmaceuticals NTM SpA ranks worse than 67.54% on this metric.
Fine Foods & Pharmaceuticals NTM SpA (FRA:9S5) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fine Foods & Pharmaceuticals NTM SpA's Enterprise Value for the quarter that ended in Mar. 2026 was €247.1 Mil.
Fine Foods & Pharmaceuticals NTM SpA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fine Foods & Pharmaceuticals NTM SpA EV-to-EBIT Related Terms
Fine Foods & Pharmaceuticals NTM SpA EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fine Foods & Pharmaceuticals NTM SpA EV-to-EBIT Chart
For the Packaged Foods subindustry, Fine Foods & Pharmaceuticals NTM SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fine Foods & Pharmaceuticals NTM SpA EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Fine Foods & Pharmaceuticals NTM SpA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fine Foods & Pharmaceuticals NTM SpA's EV-to-EBIT falls into.
Fine Foods & Pharmaceuticals NTM SpA's current Enterprise Value is €219.6 Mil.
Fine Foods & Pharmaceuticals NTM SpA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fine Foods & Pharmaceuticals NTM SpA (FRA:9S5) has a EV-to-EBIT of 17.51 as of Sep. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fine Foods & Pharmaceuticals NTM SpA and its competitors. This is near median its historical median of 17.30. According to the industry distribution chart, Fine Foods & Pharmaceuticals NTM SpA ranks #1057 out of 1565 companies in the Consumer Packaged Goods industry, placing it in the top 67.5%.
Is Fine Foods & Pharmaceuticals NTM SpA's EV-to-EBIT too high?
Fine Foods & Pharmaceuticals NTM SpA's current EV-to-EBIT of 17.51 is near median its 10-year median of 17.30. The Consumer Packaged Goods industry median EV-to-EBIT is 12.39. Fine Foods & Pharmaceuticals NTM SpA's value of 17.51 is 41.3% above this industry median. Based on the distribution chart, Fine Foods & Pharmaceuticals NTM SpA ranks #1057 out of 1565 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Fine Foods & Pharmaceuticals NTM SpA has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fine Foods & Pharmaceuticals NTM SpA's EV-to-EBIT compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Fine Foods & Pharmaceuticals NTM SpA ranks #1057 out of 1565 companies for EV-to-EBIT. This places Fine Foods & Pharmaceuticals NTM SpA in the lower half of its industry. The industry median EV-to-EBIT is 12.39. Fine Foods & Pharmaceuticals NTM SpA's value of 17.51 is 41.3% above this benchmark. While the company's 10-year median is 17.30 vs. the industry median of 12.39, Fine Foods & Pharmaceuticals NTM SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.39, based on 1,565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fine Foods & Pharmaceuticals NTM SpA's current EV-to-EBIT of 17.51 is 41.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fine Foods & Pharmaceuticals NTM SpA and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fine Foods & Pharmaceuticals NTM SpA's current EV-to-EBIT is 17.51, which is near median its own 10-year median of 17.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fine Foods & Pharmaceuticals NTM SpA stock overvalued right now?
Based on GuruFocus' analysis, Fine Foods & Pharmaceuticals NTM SpA (FRA:9S5) is currently considered Modestly Undervalued. The stock's GF Value™ is €8.87, compared to a current price of €7.16 — trading 19.3% below its estimated fair value. The current EV-to-EBIT is 17.51, which is near median its 10-year median of 17.30 and 41.3% above the Consumer Packaged Goods industry median of 12.39. Fine Foods & Pharmaceuticals NTM SpA's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fine Foods & Pharmaceuticals NTM SpA (FRA:9S5), the current EV-to-EBIT is 17.51 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fine Foods & Pharmaceuticals NTM SpA (FRA:9S5) Overvalued in 2026?
Based on GuruFocus' analysis, Fine Foods & Pharmaceuticals NTM SpA stock appears to be undervalued.
The current stock price of €7.16 is trading 19.3% below its estimated GF Value™ of €8.87.
GuruFocus considers Fine Foods & Pharmaceuticals NTM SpA to be Modestly Undervalued.
Key valuation signals for FRA:9S5:
EV-to-EBIT: 17.51 (near median its 10-year median of 17.30)
GF Value™: €8.87 vs. price of €7.16 (19.3% below fair value)
Industry Position: 41.3% above the Consumer Packaged Goods median (#1057 of 1565)
No single metric tells the full story. See the FRA:9S5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fine Foods & Pharmaceuticals NTM SpA is engaged in contract development and manufacturing of pharmaceuticals, nutraceuticals, and medical devices in solid oral forms. The company produces pharmaceutical products such as powders and granules, tablets, film tablets, and hard gelatin capsules, packed in sachets, blisters, and pillows.
63GF Score
Get the complete analysis for FRA:9S5
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9S5 has been successfully added to your 
